Obermeyer Wood Investment Counsel Lllp Has $440,000 Position in Eli Lilly and Company (NYSE:LLY)

Obermeyer Wood Investment Counsel Lllp lifted its stake in Eli Lilly and Company (NYSE:LLY) by 3.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 755 shares of the company’s stock after purchasing an additional 23 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Eli Lilly and Company were worth $440,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Simon Quick Advisors LLC boosted its position in shares of Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at $363,000. WASHINGTON TRUST Co lifted its position in Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after acquiring an additional 2,671 shares in the last quarter. Liontrust Investment Partners LLP bought a new stake in Eli Lilly and Company during the 3rd quarter worth about $8,326,000. Finally, Redhawk Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 0.9% during the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock worth $3,752,000 after buying an additional 65 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

NYSE LLY traded down $4.82 on Thursday, hitting $745.95. The company’s stock had a trading volume of 1,715,622 shares, compared to its average volume of 3,067,708. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The company’s 50-day moving average is $764.03 and its 200 day moving average is $657.67. The firm has a market cap of $708.77 billion, a PE ratio of 129.32, a PEG ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the company posted $2.09 EPS. The company’s revenue was up 28.1% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.